Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

被引：4

作者：

Bunn, Paul A., Jr. ^{[1
]}

Hirsch, Fred R. ^{[1
,2
]}

Aisner, Dara L. ^{[2
]}

机构：

[1] Univ Colorado Denver, Univ Colorado Canc Ctr, Dept Med, Div Med Oncol, Aurora, CO 80045 USA

[2] Univ Colorado Denver, Univ Colorado Canc Ctr, Dept Pathol, Aurora, CO 80045 USA

来源：

CLINICAL CANCER RESEARCH | 2014年 / 20卷 / 07期

关键词：

CELL LUNG-CANCER; ADJUVANT CHEMOTHERAPY; PREDICT SURVIVAL; VALIDATION; ASSAY; RISK;

D O I：

10.1158/1078-0432.CCR-13-3387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

pAMPK and pmTOR favorably predicted outcome in early non-small cell lung cancer (NSCLC). The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein immunohistochemistry is unlikely to be clinically useful, and numerous efforts to create predictive models to select resected patients for therapy have been unsuccessful. (C) 2014 AACR.

引用

页码：1727 / 1729

页数：3

共 50 条

[1] The Role of Lymphadenectomy in Early-Stage NSCLC
Manfredini, Beatrice
Zirafa, Carmelina Cristina
Filosso, Pier Luigi
Stefani, Alessandro
Romano, Gaetano
Davini, Federico
Melfi, Franca
CANCERS, 2023, 15 (14)
[2] Identification of early-stage lung adenocarcinoma prognostic signatures based on statistical modeling
Wu, Chunxiao
Zhang, Donglei
CANCER BIOMARKERS, 2017, 18 (02) : 117 - 123
[3] Prospective Use of Prognostic Molecular Assay Identifies Patients at Risk for Recurrence and Changes Clinical Management in Early-Stage NSCLC
Woodard, Gavitt A.
Kratz, Johannes R.
Gubens, Matthew A.
Jahan, Thierry Marie
Jones, Kirk
Theodore, Pierre
Kukreja, Jasleen
Mann, Michael
Jablons, David
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S717 - S717
[4] Gene Expression Profiling for Early-stage NSCLC
Petrosyan, Frunze
Daw, Hamed
Haddad, Abdo
Spiro, Timothy
Sood, Ruchi
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (01): : 103 - 107
[5] The role of immunotherapy in early-stage and metastatic NSCLC
Lieber, Attila
Makai, Attila
Orosz, Zsuzsanna
Kardos, Tamas
Isaac, Susil Joe
Tornyi, Ilona
Bittner, Nora
PATHOLOGY & ONCOLOGY RESEARCH, 2024, 30
[6] Developments in early-stage NSCLC: advances in radiotherapy
Verstegen, N. E.
Lagerwaard, F. J.
Senan, S.
ANNALS OF ONCOLOGY, 2012, 23 : 46 - 51
[7] Clinical Utility of Tumor-Naive Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC
Hong, Tae Hee
Hwang, Soohyun
Dasgupta, Abhijit
Abbosh, Chris
Hung, Tiffany
Bredno, Joerg
Walker, Jill
Shi, Xiaojin
Milenkova, Tsveta
Horn, Leora
Choi, Joon Young
Lee, Ho Yun
Cho, Jong Ho
Choi, Yong Soo
Shim, Young Mog
Chai, Shoujie
Rhodes, Kate
Roychowdhury-Saha, Manami
Hodgson, Darren
Kim, Hong Kwan
Ahn, Myung-Ju
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (11) : 1512 - 1524
[8] Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Han, Yunwei
Yu, Zhihao
Wen, Shaoyan
Zhang, Bin
Cao, Xuchen
Wang, Xin
BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 483 - 490
[9] Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Yunwei Han
Zhihao Yu
Shaoyan Wen
Bin Zhang
Xuchen Cao
Xin Wang
Breast Cancer Research and Treatment, 2012, 131 : 483 - 490
[10] A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel
Ying, Lisha
Lu, Tingting
Tian, Yiping
Guo, Hui
Wu, Conghui
Xu, Chen
Jin, Jiaoyue
Zhu, Rui
Liu, Pan
Yang, Ying
Yang, Chaodan
Ding, Wenyu
Xu, Chenyang
Huang, Minran
Ma, Zhengxiao
Zhang, Yuting
Zhuo, Yue
Zou, Ruiyang
Su, Dan
LUNG CANCER, 2024, 195

← 1 2 3 4 5 →